• Japanese
  • Korean
  • Chinese
Cover Image

Needle-Free Delivery: Technology and Market Forecast 2014-2024

Needle-free delivery - discover technological and commercial prospects

What does the future hold for the needle-free delivery market? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 187 page report provides 103 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects.

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

  • Robert E. Sievers, CEO and President, Aktiv-Dry LLC
  • David Hoey, CEO, Vaxxas
  • Professor Mark Kendall, Inventor of the Nanopatch and Co-Founder of Vaxxas
  • John Turanin, Vice President and General Manager, Zogenix Technologies
  • Mark Logomasini, President and CEO, Bioject Medical Technologies

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting of two world-level submarkets to 2024:

  • Jet injectors market
  • Competing needle-free technology market

The competing needle-free technology market is further segmented into:

  • Novel needle technology (includes microneedles and pen needles)
  • Inhaler technology
  • Patch technology

Our investigation shows business research and analysis with individual revenue forecasts and discussions. How will those needle-free technologies expand? Which applications will generate most money? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

What are the prospects in the leading regions and countries?

Events and progress worldwide will influence the market. In our study you will find individual revenue forecasts to 2024 for 10 national markets:

  • US
  • Japan
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • India
  • Row

Many opportunities exist within the needle-free delivery market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Leading companies and potential for market growth

Overall world revenue for the needle-free delivery market will reach $1.2bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:

  • Antares Pharma
  • Zogenix
  • Bioject Medical Technologies
  • 3M
  • Medical International Technology (MIT)
  • D'Antonio Consultants International (DCI)
  • PharmaJet
  • Akra Dermojet
  • Injex Pharma
  • Glide Pharma

In general, a company profile gives you the following information:

  • Overview of the company, including its history in the market
  • Discussion of a company's activities and outlook including descriptions of leading products
  • Recent financial results
  • Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures

What issues will affect the needle-free delivery market?

Our new report discusses issues and events affecting the needle-free delivery market. You will find discussions, including qualitative analyses:

  • Developments in transdermal delivery
  • Growing demand for minimally invasive delivery methods
  • Mass immunisation programmes across the globe
  • Booming global vaccine market
  • Shift towards home administration settings
  • Increasing regulatory scrutiny
  • Inefficient manufacturing processes leading to costly needle-free technologies

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Needle-Free Delivery: Technology and Market Forecast 2014-2024 & Prospects for Leading Companies report helps you

In summary, our 187 page report gives you the following knowledge:

  • Revenues forecasts to 2024 for the overall world needle-free delivery market, 2 submarkets and 3 leading segments - discover the industry's prospects, finding promising places for investments and revenues
  • Assessment of 10 leading companies, and others, discovering activities and outlooks
  • Market forecasting to 2024 for 10 leading regions and countries - USA, Japan, Germany, France, UK, Spain, Italy, Rest of

Europe, India, China and RoW

  • View opinions from our survey, seeing 5 interviews with leading authorities
  • Investigation of competition and opportunities influencing sales
  • Discussion of what stimulates and restrains the needle-free delivery market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the needle-free delivery market. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Sector Highlights
  • 1.2. Aim, Scope and Format of This Report
  • 1.3. Chapter Outline
  • 1.4. Research and Analysis Methods
  • 1.5. Glossary of Terms Relating to the Report

2. Introduction to Needle-Free Delivery of Drugs/Vaccines

  • 2.1. What is Needle-Free Technology?
    • 2.1.1. History of Needle-Free Injections (NFI)
  • 2.2. Why the Need For Needle-Free Delivery Technology?
    • 2.2.1. Needle Stick Injury
      • 2.2.1.1. Blood-Borne Pathogens and Needle Stick Injury
      • 2.2.1.2. Accidental Needle Stick Injury: A Serious Healthcare Problem
  • 2.3. Clinical Settings Where Needle-Free Delivery Technology Will Be Beneficial
    • 2.3.1. Pain Management
      • 2.3.1.1. Pain Management: Using NFI Devices to Administer Lidocaine
    • 2.3.2. Vaccine Delivery: Improving Immune Response
      • 2.3.2.1. The Global Vaccine Market, 2014-2024
      • 2.3.2.2. Needle-Free Vaccine Delivery
      • 2.3.2.3. Mass Immunisation
    • 2.3.3. Insulin Delivery For Diabetics
    • 2.3.4. Paediatric Injections
    • 2.3.5. Other Uses For Needle-Free Injection Technology
  • 2.4. Advantages and Disadvantages of Needle-Free Injections
  • 2.5. The Needle-Free Delivery Market
    • 2.5.1. Jet Injectors
      • 2.5.1.1. Concerns About Multi-use Nozzle Jet injectors (MUNJIs)
      • 2.5.1.2. Strengths and Weaknesses of Jet Injectors
    • 2.5.2. Competing Needle-Free Technologies
      • 2.5.2.1. Novel Needle Technology
        • 2.5.2.1.1. Pen Needles
        • 2.5.2.1.2. Microneedles
        • 2.5.2.1.3. Hollow Microneedles
        • 2.5.2.1.4. Solid Coated Microneedles
        • 2.5.2.1.5. Solid Biodegradable Microneedles
        • 2.5.2.1.6. Solid Uncoated Microneedles
        • 2.5.2.1.7. Selection of Microneedles
      • 2.5.2.2. Inhaler Technology
      • 2.5.2.3. Transdermal Patch Technology
  • 2.6. Regulation of the Needle-Free Delivery Market
    • 2.6.1. The US Regulation System
      • 2.6.1.1. Combination Products
      • 2.6.1.2. FDA Statement Clamps Down On Delivery of Medications in Non-approved Needle-Free Devices
    • 2.6.2. The European Regulation System
      • 2.6.2.1. Post Marketing Surveillance in the EU

3. The Global Needle-Free Injection Device Market, 2014-2024

  • 3.1. The Needle-Free Delivery Technology Market: Overview
  • 3.2. The Needle-Free Delivery Technology Market by Segments, 2012-2013
  • 3.3. The Needle-Free Delivery Market Forecast, 2014-2024
  • 3.4. Needle-Free Delivery Technology: Market Trends, 2014-2024

4. The Jet Injectors Technology Market, 2014-2024

  • 4.1. The Jet Injectors Market, 2012-2013
  • 4.2. The Jet Injectors Market Forecast, 2014-2024
  • 4.3. Leading Devices in the Jet Injectors Market, 2014
    • 4.3.1. Biojector 2000 (Bioject Medical Technologies)
    • 4.3.2. SUMAVEL DosePro (Zogenix)
    • 4.3.3. E-Jet 100 (Eurojet Medical)
    • 4.3.4. STRATIS (Pharmajet)
    • 4.3.5. ZetaJet (Bioject Medical Technologies)
    • 4.3.6. LectraJet (D'Antonio Consultants International)
    • 4.3.7. Med-Jet (Medical International Technologies)
    • 4.3.8. Vision (Antares Pharma)
    • 4.3.9. Glide System (Glide Pharmaceutical Technologies)
    • 4.3.10. AdvantaJet (Activa Brand Products)
    • 4.3.11. J-Tip (National Medical Products)
    • 4.3.12. SQ-Pen (Diabetes Management International)
    • 4.3.13. Vitajet3 (Bioject Medical Technologies)
    • 4.3.14. Penjet (Penjet Corporation)
    • 4.3.15. INJEX30 (Injex)
  • 4.4. Jet Injectors Development Pipeline, 2014
    • 4.4.1. Zeneo (Crossject Medical Technologies)
    • 4.4.2. Jupiter Jet (Bioject Medical Technologies)
    • 4.4.3. Iject (Bioject Medical Technologies)
      • 4.4.3.1. Iject R (Bioject Medical Technologies)
    • 4.4.4. Relday (Zogenix)
  • 4.5. Concluding Remarks

5. Competing Needle-Free Technology Market, 2014-2024

  • 5.1. Competing Needle-Free Technologies: Overview
  • 5.2. Competing Needle-Free Technology Market, 2012-2013
  • 5.3. Competing Needle Free Technologies Market Forecast by Segments, 2014-2024
  • 5.4. Novel Needle Technology Market, 2013
    • 5.4.1. Novel Needle Technology Market Forecast, 2014-2024
    • 5.4.2. Leading Products in the Microneedle Technology Market, 2014
    • 5.4.3. Microneedle Patches for Vaccine Delivery, 2014
      • 5.4.3.1. Microneedle Patch for the Polio Vaccine (Georgia Tech's School of Chemical and Biomolecular Engineering)
      • 5.4.3.2. AdminPen (nanoBioSciences)
      • 5.4.3.3. PKA SoftTouch (PKA SoftTouch Corp)
      • 5.4.3.4. DrugMAT (TheraJect)
      • 5.4.3.5. MicroCor (Corium International)
      • 5.4.3.6. Nanopatch (Vaxxas)
      • 5.4.3.7. ZP Patch Technology (Zosana)
  • 5.5. Inhaler Technology Market, 2013
    • 5.5.1. Inhaler Technology Market Forecast, 2014-2024
    • 5.5.2. Inhalers in the Asthma Market, 2014
    • 5.5.3. Inhalers in the Insulin Market, 2014
    • 5.5.4. Inhalers in the Vaccine Market, 2014
  • 5.6. The Patch Technology Market, 2013
    • 5.6.1. The Patch Technology Market Forecast, 2014-2024
    • 5.6.2. Drug Patches in the Market, 2014
  • 5.7. Other Competing Needle-free delivery Technology in development
    • 5.7.1. Magnetic Injection
    • 5.7.2. Laser Injection
    • 5.7.3. Vaccine Delivery Using Micro-Shock Waves (Indian Institute of Science, Bangalore)
    • 5.7.4. Nanotechnology Syringes (Gwangju Institute of Science and Technology, South Korea)
    • 5.7.5. Nanotechnology Implant (University of California, San Francisco)

6. Leading National Needle-Free Delivery Markets, 2014-2024

  • 6.1. Leading National Breakdown of the Needle-Free Delivery Market, 2012-2013
  • 6.2. The Leading National Needle-Free Delivery Market Forecast, 2014-2024
  • 6.3. The US Needle-Free Delivery Market Forecast, 2014-2024
  • 6.4. The European Needle-Free Delivery Market, 2013
    • 6.4.1. The European Needle-Free Delivery Market Forecast, 2014-2024
      • 6.4.1.1. The German Needle-Free Delivery Market Forecast, 2014-2024
      • 6.4.1.2. The French Needle-Free Delivery Market Forecast, 2014-2024
      • 6.4.1.3. The Italian Needle-Free Delivery Market Forecast, 2014-2024
      • 6.4.1.4. The Spanish Needle-Free Delivery Market Forecast, 2014-2024
      • 6.4.1.5. The UK Needle-Free Delivery Market Forecast, 2014-2024
  • 6.5. The Japanese Needle-Free Delivery Market Forecast, 2014-2024
  • 6.6. The Chinese Needle-Free Delivery Market Forecast, 2014-2024
  • 6.7. The Indian Needle-Free Delivery Market Forecast, 2014-2024

7. Leading Companies in the Needle-Free Delivery Market 2014

  • 7.1. Antares Pharma
    • 7.1.1. Sales and Performance Analysis
    • 7.1.2. Product Sales, 2012
    • 7.1.3. Revenue by Region, 2012
    • 7.1.4. Revenue by Major Customers, 2011-2012
    • 7.1.5. Sales and Performance Analysis, 3Q 2013
    • 7.1.6. Technology of Antares Pharma
      • 7.1.6.1. Pressure Assisted Injection Devices
      • 7.1.6.2. Transdermal Gel System
    • 7.1.7. Marketed Products, 2014
    • 7.1.8. Pipeline Products, 2014
  • 7.2. Zogenix
    • 7.2.1. Sales and Performance Analysis
    • 7.2.2. Sales by Segment, 2013
    • 7.2.3. Needle-Free Products
      • 7.2.3.1. Marketed Products, 2014
        • 7.2.3.1.1. Sumavel® DosePro®: Rapid Acting Migraine Relief
        • 7.2.3.1.2. Zohydro™ ER (hydrocodone bitartrate) Extended-Release Capsules
        • 7.2.3.1.3. Zohydro™ ER Approval: Cause for Controversy?
        • 7.2.3.1.4. Pipeline Products, 2014
    • 7.2.4. Collaborations
      • 7.2.4.1. Co-promotion of Migranal Nasal Spray with Valeant
    • 7.2.5. Manufacturing
  • 7.3. Bioject Medical Technologies
    • 7.3.1. Sales and Performance Analysis
    • 7.3.2. Sales Performance Analysis by Products
    • 7.3.3. Sales and Performance Analysis, 3Q 2012-2013
    • 7.3.4. Bioject's Sales Revenue Setbacks
    • 7.3.5. Collaborations
      • 7.3.5.1. Navy Malaria Study: Utilises Bioject's B2000 Technology
      • 7.3.5.2. Cyto Pulse Sciences: Clinical Trials for an HIV/DNA vaccine
      • 7.3.5.3. CDA intradermal influenza study
      • 7.3.5.4. MPI Research: Seeking Drug/Device Combinations
      • 7.3.5.5. World Health Organisation (WHO): The Push to Eradicate Infectious Disease in Developing Countries
    • 7.3.6. Needle-Free Products
      • 7.3.6.1. Biojector® 2000: Adaptable Power Source Allows Use in Home and Mass Vaccination Setting
      • 7.3.6.2. Vitajet™: Low-cost Insulin Delivery System
      • 7.3.6.3. ZetaJet™: Auto-disable Feature Improves User Safety
    • 7.3.7. Needle-Free Injection Device Pipeline
      • 7.3.7.1. Intradermal Pen Injector: Targeted Drug Delivery
      • 7.3.7.2. Iject®: Providing Tailored Depth of Penetration
      • 7.3.7.3. Jupiter Jet: Multi Dosing With Single Loaded Syringe
  • 7.4. 3M
    • 7.4.1. Sales and Performance Analysis
    • 7.4.2. 3M Drug Delivery Systems
      • 7.4.2.1. Inhalation
      • 7.4.2.2. Transdermal patch
      • 7.4.2.3. Microneedles
  • 7.5. Medical International Technology (MIT)
    • 7.5.1. Sales and Performance Analysis
    • 7.5.2. Increased Product Awareness Through Globalisation
      • 7.5.2.1. Further Expansion in China
    • 7.5.3. Products
      • 7.5.3.1. Med Jet
  • 7.6. D'Antonio Consultants International (DCI)
    • 7.6.1. Needle-Free Products
      • 7.6.1.1. LectraJet®: Lightweight Device Reduces User Fatigue
    • 7.6.2. Needle-Free Injection Device Pipeline
      • 7.6.2.1. Low Workload Jet Injector: Single-shot Manual System
      • 7.6.2.2. Multi Channel Jet Injector: For Simultaneous Vaccine Delivery
  • 7.7. PharmaJet
    • 7.7.1. Needle-Free Products
      • 7.7.1.1. STRATIS®: Drug Delivery in Less Than a Second
      • 7.7.1.2. Applications
    • 7.7.2. Collaborations: Pursuing a Drug/Device Combination for Vaccine Administration
  • 7.8. Akra Dermojet
    • 7.8.1. Needle-Free Products
      • 7.8.1.1. DERMOJET® “HR”: User-Friendly Design Allows Use in High Intensive Applications
      • 7.8.1.2. DERMOJET Polymedical®: Interchangeable Injection Tips Reduces Risk of Contamination
      • 7.8.1.3. Automatic DERMOJET®
  • 7.9. Injex Pharma
    • 7.9.1. Injex 30
      • 7.9.1.1. Injex 30's Applications
    • 7.9.2. Injex's Worldwide Distribution
      • 7.9.2.1. Exclusive Distributor Agreement with Russia's Medici Ltd.
      • 7.9.2.2. Chinese SFDA approval
      • 7.9.2.3. NHS's Withdrawal of Injex30
  • 7.10. Glide Pharma
    • 7.10.1. Applications
      • 7.10.1.1. Glide SDI system's Advantages
    • 7.10.2. Injecting Solid Formulations
    • 7.10.3. Pharmaceutical Companies
    • 7.10.4. Collaboration with Pfenex Inc. to Aid Delivery of Solid Dose Vaccine

8. Qualitative Analysis of the Needle-Free Delivery Market, 2014-2024

  • 8.1. SWOT Analysis of the Needle-Free Delivery Market, 2014-2024
  • 8.2. Strengths
    • 8.2.1. Strong Growth in the Biologic Drug Market
    • 8.2.2. Increasing Development in Transdermal Delivery
    • 8.2.3. No Specialist Training Required for Drug/Vaccine Delivery
    • 8.2.4. Eliminating the Cold Chain Problem
    • 8.2.5. Reduction in Needle Stick Injuries
  • 8.3. Weaknesses
    • 8.3.1. Healthcare Practitioners are not Familiar with Novel Delivery Systems
    • 8.3.2. Current Inefficient Manufacturing Processes Lead to Costly Needle-Free Technology
    • 8.3.3. Current Technology is Very Expensive
  • 8.4. Opportunities
    • 8.4.1. Emerging Economies Offer Significant Growth Opportunities
    • 8.4.2. Mass Immunisation Programs Around the World
    • 8.4.3. Increasing Global Diabetes Population
    • 8.4.4. Shift Towards Home Administration Setting
    • 8.4.5. Extending Life Cycle of Drugs
  • 8.5. Threats
    • 8.5.1. Traditional Needles and Syringes are Very Cheap to Mass Produce
      • 8.5.1.1. Needle and Syringes with Anti Needle-Stick Injury Technology
    • 8.5.2. Greater Regulatory Scrutiny
    • 8.5.3. Limited Clinical Data
    • 8.5.4. Medical Device Excise Tax

9. Expert Opinion

  • 9.1. Interview with Robert E. Sievers, CEO and President, Aktiv-Dry LLC, and Professor, Department of Chemistry and Biochemistry Center for Pharmaceutical Biotechnology, University of Colorado, Boulder
    • 9.1.1. Aktiv-Dry's PuffHaler
    • 9.1.2. The Benefits of Inhaler Technology
    • 9.1.3. The Competitive Landscape for Measles Inhaler Vaccines
    • 9.1.4. ACTIV DRY'S Collaborations
    • 9.1.5. The Challenges to Introduction Novel Inhaler Technology
  • 9.2. Interview with David Hoey, CEO, Vaxxas
    • 9.2.1. Vaxxas's Nanopatch™ technology
    • 9.2.2. The Advantages of Using Nanopatch Technology in Developed and Developing Markets
    • 9.2.3. The Challenges of Manufacturing Patch Technology
    • 9.2.4. The Future for the Nanopatch Technology
  • 9.3. Professor Mark Kendall, Inventor of the Nanopatch and Co-founder of Vaxxas
    • 9.3.1. Microneedles: Proof of Concept to Commerical Product
    • 9.3.2. Needle Delivery Market is Still Strong
    • 9.3.3. The Microneedle Market
  • 9.4. Interview with John Turanin, Vice President and General Manager, Zogenix Technologies
    • 9.4.1. The Use of Gas Power in Jet Injectors
    • 9.4.2. The Incentives for Drug Companies in Adopting Needle-Free Delivery
    • 9.4.3. Regulating the Needle-Free Delivery Technology Market
    • 9.4.4. Regional Market Forecasts for Jet Injectors
    • 9.4.5. Jet Injectors: Competitive Space and Restraints on the Market
    • 9.4.6. Regional Market Forecasts for Jet Injectors
    • 9.4.7. Jet Injectors: Competitive Space and Restraints on the Market
  • 9.5. Interview with Mark Logomasini, President and CEO, Bioject Medical Technologies
    • 9.5.1. The Spring-Powered, Gas-Powered and Battery Powered Jet Injector Markets
    • 9.5.2. Other Competing Needle-Free Delivery Platforms
    • 9.5.3. Regulations Determine Jet Injector Market
    • 9.5.4. Small Needle Free Delivery Companies Requires Large External Capital

10. Conclusions

  • 10.1. The Needle-Free Delivery Market, 2014-2024
  • 10.2. Transdermal Delivery For Vaccine Delivery
  • 10.3. Biologic Drugs are a Major Driver of the Needle Free Delivery Market
  • 10.4. Strong Pipeline Will Drive the Competing Needle-Free Injection Technology Market
  • 10.5. Concluding Remarks

List of Tables

  • Table 2.1: The Vaccine Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2012-2024
  • Table 2.2: Rationale For Needle-Free Vaccine Delivery
  • Table 2.3: Key Examples of Needle-Free Vaccine Delivery Systems, 2014
  • Table 2.4: Key Examples of Needle-Free Insulin Delivery Systems for Diabetics, 2014
  • Table 2.5: Advantages and Disadvantages of Needle-Free Injections
  • Table 2.6: Classification of Jet Injectors by Method of Propulsion
  • Table 2.7: Strengths and Weaknesses of Jet Injectors
  • Table 2.8: Pen Needle Technology by Needle Length
  • Table 2.9: FDA Guidance on Regulation of Needle-Free Injectors, 2014
  • Table 3.1: The Needle-Free Delivery Market: Revenue ($m), Market Share (%) by Segment, 2012-2013
  • Table 3.2: The Needle-Free Delivery Market: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 4.1: The Jet Injector Market: Revenue ($m), Market Share (%), 2012-2013
  • Table 4.2: The Jet Injector Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 4.3: Leading Devices in the Jet Injectors Market , 2014
  • Table 4.4: The Jet Injector Development Pipeline, 2014
  • Table 4.5: Crossject: Zeneo Development Pipeline, 2014
  • Table 5.1: The Competing Needle-Free Technology Market: Revenue ($m), Market Share (%) by Segment, 2012-2013
  • Table 5.2: The Competing Needle-Free Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%) 2012-2024
  • Table 5.3: The Novel Needle Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.4: Leading Products in the Microneedle Technology Market, 2014
  • Table 5.5: Leading Products in the Microneedle Technology Pipeline, 2014
  • Table 5.6: The Inhaler Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.7: Leading Inhalers in the Asthma Market, 2014
  • Table 5.8: Leading Inhalers in the Insulin Market, 2014
  • Table 5.9: Vaccine Inhalers Currently Under Development, 2014
  • Table 5.10: The Patch Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.11: Drug Patches in the Market, 2014
  • Table 6.1: The Leading National Needle-Free Delivery Markets: Revenue ($m), Market Share (%), 2012-2013
  • Table 6.2: The Leading National Needle-Free Delivery Market Forecasts: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.3: The US Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.4: The Leading National European Needle-Free Delivery Markets: Revenue ($m), Market Shares (%) by Country, 2012-2013
  • Table 6.5: The European Needle-Free Delivery Markets: Revenue ($m), CAGR (%), AGR (%) by Country, 2012-2024
  • Table 6.6: The German Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.7: The French Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.8: The Italian Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.9: The Spanish Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.10: The UK Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.11: The Japanese Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.12: The Chinese Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.13: The Indian Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 7.1: Antares Pharma: Revenue ($m), AGR (%), 2010-2012
  • Table 7.2: Antares Pharma: Revenue ($m), Revenue Shares (%) by Business Segment, 2012
  • Table 7.3: Antares Pharma: Revenue ($m), Revenue Shares (%) by Product Type, 2012
  • Table 7.4: Antares Pharma: Revenue ($m), Revenue Shares (%) by Region, 2012
  • Table 7.5: Antares Pharma: Revenue ($m) by Customer, 2011-2012
  • Table 7.6: Antares Pharma: Revenue ($m), Total 1Q, 2Q, 3Q, 2012-2013
  • Table 7.7: Antares Pharma: Products Under Development, 2014
  • Table 7.8: Zogenix: Revenue ($m), AGR (%), 2010-2013
  • Table 7.9: Zogenix: Revenue ($m), Revenue Shares (%) by Segment, 2013
  • Table 7.10: Bioject: Revenue ($m), Revenue Shares (%) by Product Line, 2010
  • Table 7.11: Bioject: Revenue ($m), Total 1Q, 2Q, 3Q 2012-2013
  • Table 7.12: Bioject: Summary of Technologies
  • Table 7.13: 3M: Revenue ($bn), Revenue Shares (%) by Business Segment, 2012-2013
  • Table 7.14: MIT: Revenue ($m), AGR (%), 2009-2013
  • Table 7.15: MIT: Products, 2014
  • Table 7.16: Akra Dermojet: Summary of Technology
  • Table 7.17: Other Needle-Free Delivery Companies, 2014
  • Table 8.1: SWOT Analysis of the Needle-free Delivery Market, 2014-2024
  • Table 8.2: Average Price For Needle-Free Drug/Vaccine Delivery Technology, 2014
  • Table 8.3: Patent Expiries For Leading Drugs, 2014-2016
  • Table 10.1: The Needle-Free Delivery Market Segments: Revenue ($m), AGR (%), CAGR (%), 2013, 2018 & 2024

List of Figures

  • Figure 2.1: Percentage (%) of Needle-stick Injuries During the Timeline of Use to Disposal of a Device
  • Figure 2.2: The Vaccine Market Forecast: Revenue ($bn), AGR (%), 2012-2024
  • Figure 3.1: The Needle-Free Delivery Market: Revenue ($m) by Segment, 2013
  • Figure 3.2: The Needle-Free Delivery Market: Market Share (%) by Segment, 2013
  • Figure 3.3: The Total Needle-Free Delivery Market: Revenue ($m), AGR (%), 2012-2024
  • Figure 4.1: The Jet Injector Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.1: The Competing Needle-Free Technology Market: Revenue ($m) by Segment, 2013
  • Figure 5.2: The Competing Needle-Free Technology Market: Market Share (%) by Segment, 2013
  • Figure 5.3: The Competing Needle-Free Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Figure 5.4: The Novel Needle Technology Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.5: The Inhaler Technology Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.6: The Patch Technology Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.1: The Needle-Free Delivery Market: Revenue ($m) in Leading National Markets, 2013
  • Figure 6.2: The Needle-Free Delivery Market: Market Share (%) in Leading National Markets, 2013
  • Figure 6.3: The US Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.4: The Leading National European Needle-Free Delivery Markets: Revenue ($m) by Country, 2013
  • Figure 6.5: The Leading National European Needle-Free Delivery Markets: Market Share (%) by Country, 2013
  • Figure 6.6: The European Needle-Free Delivery Markets Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.7: The German Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.8: The French Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.9: The Italian Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.10: The Spanish Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.11: The UK Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.12: The Japanese Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.13: The Chinese Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 6.14: The Indian Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 7.1: Antares Pharma: Revenue ($m), AGR (%), 2010-2012
  • Figure 7.2: Antares Pharma: Revenue ($m) by Business Segment, 2012
  • Figure 7.3: Antares Pharma: Revenue Shares (%) by Business Segment, 2012
  • Figure 7.4: Antares Pharma: Revenue ($m) by Product Type, 2012
  • Figure 7.5: Antares Pharma: Revenue Shares (%) by Region, 2012
  • Figure 7.6: Antares Pharma: Revenue ($m), Total 1Q, 2Q, 3Q, 2012-2013
  • Figure 7.7: Zogenix: Revenue ($m), AGR (%), 2010-2013
  • Figure 7.8: Zogenix: Revenue Shares (%) by Segment, 2013
  • Figure 7.9: Bioject: Revenue ($m), 2010-2012
  • Figure 7.10: Bioject: Revenue ($m) by Product Line, 2010
  • Figure 7.11: Bioject: Revenue ($m), 1Q, 2Q, 3Q 2012-2013
  • Figure 7.12: 3M: Revenue ($bn) by Business Segment, 2013
  • Figure 7.13: MIT: Revenue ($m), AGR (%), 2009-2013
  • Figure 8.1: The Transport Process For a Vaccine
  • Figure 10.1: The Total Needle-Free Delivery Market: Revenue ($m), 2013, 2018 & 2024
  • Figure 10.2: The Total Needle-Free Delivery Market: Revenue ($m) by Segment, 2013, 2018 & 2024

Companies Listed

  • 3M
  • 4P
  • Therapeutics
  • Activa Brand Products
  • AcuShot
  • Akra Dermojet
  • AKTIV-DRY
  • Alkermes
  • Allen & Hanburys
  • AllTranz
  • Altea Development Corporation
  • Altus Formulation
  • ALZA Pharmaceuticals
  • Amerisource Bergen Corporation
  • Anesiva
  • Antares Pharma
  • Aradigm
  • Astellas Pharma
  • AstraZeneca
  • B Braun
  • Battelle
  • Becton Dickinson
  • Berlex Laboratories
  • Bespak
  • Bioject Medical Technologies
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cambridge Consultants
  • Cardinal Health Inc.
  • Corium International
  • Covidien
  • Crossject Medical Technology
  • CSL Behring
  • CSL Limited
  • CVS Pharmacy (CVS.com)
  • Cydex (subsidiary by Ligand)
  • Cyto Pulse Sciences
  • D'Antonio Consultants International
  • Daewoong Pharmaceuticals
  • Debiotech
  • Dr. Reddy's Laboratories
  • Durect
  • Echo Therapeutics
  • Eli Lilly
  • Eloquest Healthcare
  • EMD Serono (subsidiary MERCK KGAA)
  • Endo Pharmaceuticals
  • Eternity Healthcare
  • Ethical Holdings
  • Eurojet Medical
  • Evonik Industries
  • Felton International
  • Ferndale Pharma Group
  • Ferring
  • Generex
  • GlaxoSmithKline
  • Glide Pharma
  • Hangzhou Hema Medical equipment Co. Ltd
  • Injex Pharma
  • Intercell
  • IOMAI
  • Janssen Pharmaceuticals
  • JCR Pharmaceuticals
  • Jiangsu Hualan MIT Medical Technology (MIT China)
  • Johnson and Johnson
  • Key Pharmaceuticals
  • Kroger
  • Mallinckrodt Pharmaceuticals
  • MannKind
  • McKesson Corporation
  • MEDA
  • Medical House Products Limited
  • Medical International Technologies
  • MEDICI Ltd.
  • MedImmune
  • Merck Sorono
  • MGlas AG
  • Mystic Pharmaceuticals
  • nanoBioSciences
  • NanoPass Technologies
  • Napp Pharmaceuticals
  • National Medical Products
  • Nektar Therapeutics
  • Neumaura Pharma
  • Nicobrand Limited
  • Novartis
  • Novo Nordisk
  • Novogyne Pharmaceuticals
  • Nycomed
  • Nypro Limited
  • Owen Mumford
  • Pantec Biosolutions
  • Parke-Davis
  • Patheon UK
  • PenJet Corporation
  • Pfenex
  • Pfizer
  • Pharmacia & Upjohn
  • PharmaJet
  • Philips Medical
  • PKA SoftTouch Corp
  • PowderJect Pharmaceuticals (subsidiary of Pfizer)
  • PowerMed (acquired by Pfizer)
  • Procter and Gamble
  • ProStrakan
  • Pulse Needle-free Systems
  • Purdue Pharma
  • Sanofi
  • Schering
  • Schuco
  • Schwarz Pharma
  • Serum Institute of India
  • Shire
  • Shwarz-Pharma
  • Somerset Pharmaceuticals
  • Spruyt hillen
  • STAT Medical Devices
  • Syke Pharma
  • Syneron
  • Taizhou Amazon Investment Center
  • Takeda
  • Tapemark
  • Team Consulting
  • Teva Pharmaceutical
  • The Medicines Company
  • TheraJect
  • TheraTech
  • Trinity-Chiesi
  • UCB
  • Valeant
  • Valeritas
  • VAXXAS
  • Vygon
  • Vyteris
  • Watson Pharmaceuticals
  • Ypsomed Holiding
  • Zeltrix
  • Zogenix
  • Zosano Pharma
  • Zydus Cadil
  • Other Organisations Mentioned in This Report
  • Ankara University
  • Australian Institute of Bioengineering and Nanotechnology, University of Queensland
  • Biomedicine International
  • CDC Measles Eradication Committee
  • Center for Biologics Evaluation and Research (CBER) (US)
  • Center for Drug Evaluation and Research (CDER) (US)
  • Centers for Disease Control and Prevention (CDC)
  • Echo Therapeutics
  • Emory University
  • European Union (EU)
  • European Union Council
  • Gates Foundation
  • Georgia Tech's School of Chemical and Biomolecular Engineering
  • Gwangju Institute of Science and Technology
  • Harvard University
  • Indian Institute of Science
  • Karolinska Institutet
  • Leiden University Medical Centre
  • Massachusetts Institute of Technology (MIT)
  • Medical Products Agency (Sweden)
  • Medicine In Need (MEND)
  • MPI Research
  • National Competent Authorities (NCAs)
  • National Health Services (NHS)
  • National Institute of Health (NIH)
  • Population Council
  • Royal College of Nursing (RCN)
  • Seoul National University
  • The Accidental Blood Exposure Study Task Force (GERES) (France)
  • The Centre for Devices and Radiological Health (CDRH)
  • The China Food and Drug Administration (CFDA) (China)
  • The China State Food and Drug Administration (SFDA) (China)
  • The Food and Drug Administration (FDA) (US)
  • The Global Polio Eradication Initiative (GPEI)
  • The International Diabetes Federation (IDF)
  • The Ministry of Health of Oman
  • The Ministry of Health, Labour, and Welfare (MHLW)
  • The National Institute of Allergy and Infectious Diseases (NIAID)
  • The National Institute of Health (NIH)
  • The Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)
  • The Program for Appropriate Technology in Health (PATH)
  • The Swedish Institute for Infectious Disease Control
  • The University of Colorado Cooperative Institute for Research in Environmental Sciences (CIRES)
  • The US Army Medical Research Institute of Infectious Diseases (USAMRIID)
  • U.S. Navy
  • University Erlangen-Nurnberg
  • University of California
  • University of Colorado
  • University of Oxford
  • US Military
  • World Health Organisation (WHO)
Show More
RELATED REPORTS
Pricing